Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.

Bhatt D. L., Szarek M., Pitt B., Cannon C. P., Leiter L. A., McGuire D. K., ...Daha Fazla

The New England journal of medicine, cilt.384, ss.129-139, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 384
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1056/nejmoa2030186
  • Dergi Adı: The New England journal of medicine
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, Abstracts in Social Gerontology, AgeLine, BIOSIS, CAB Abstracts, Chemical Abstracts Core, CINAHL, Educational research abstracts (ERA), EMBASE, Food Science & Technology Abstracts, Gender Studies Database, International Pharmaceutical Abstracts, MEDLINE, MLA - Modern Language Association Database, Public Affairs Index, Veterinary Science Database
  • Sayfa Sayıları: ss.129-139
  • İstanbul Üniversitesi Adresli: Evet

Özet

In a trial involving 10,584 patients with diabetes and chronic kidney disease, sotagliflozin resulted in fewer total deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure than placebo. Diarrhea, mycotic infections, and diabetic ketoacidosis occurred with sotagliflozin.